IFNG and neoplasm: In response to anti-PD-L1 treatment with Atezolizumab, mice engrafted with human NK cells and PD-L1- K562 myeloid leukemia cells demonstrated significantly elevated levels of granzyme B, IFN-γ, and CD107a, contributing to notable reductions in tumor burden and significant improvement in survival over the placebo controls (25).